Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
Saved in:
| Title: | Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. |
|---|---|
| Authors: | Denlinger CS; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. Crystal.Denlinger@fccc.edu., Keedy VL; Department of Medicine (Hematology and Oncology), Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Moyo V; Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA., MacBeath G; Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA., Shapiro GI; Dana-Farber Cancer Institute, Boston, MA, USA. |
| Source: | Investigational new drugs [Invest New Drugs] 2021 Dec; Vol. 39 (6), pp. 1604-1612. Date of Electronic Publication: 2021 Jul 11. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-0646 |
|---|---|
| DOI: | 10.1007/s10637-021-01145-y |
